Articles On Impression Healthcare (ASX:IHL)

Shareholders in Incannex Healthcare (ASX: IHL) (NASDAQ: IXHL) have voted overwhelmingly in favour of a scheme to redomicile the company’s headquarters to the US. Approximately 99.64% of shareholders and 99.93% of optionholders have given th...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week   In July of this year, Austral...

Incannex subsidiary Psychennex prepares investigational new drug application for US FDA Application crucial to moving forward psilocybin assisted psychotherapy (Psi-GAD) trial in US IHL says the IND preparation demonstrates its confidence...

Incannex Healthcare (IHL) is charging ahead with another US application for an IND through its subsidiary psychedelic company, Psychennex Psychennex kicks off preparations for the application to the FDA for its psilocybin-assisted psych...

Incannex Healthcare (ASX: IHL) subsidiary Psychennex Pty Ltd has started preparing an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for a psilocybin-assisted psychotherapy development program (Psi-G...

Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has received approval from the US Food and Drug Administration (FDA) to conduct an investigational new drug (IND) opening trial for lead candidate IHL-42X in the US. The p...

Incannex Healthcare’s (IHL) subsidiary, Clarion Clinics Group, is initiating recruitment for subjects to test its PAT treatments Recruitment protocols include a thorough pre-treatment assessment process, including psychiatric evaluation,...

Incannex Healthcare’s (ASX: IHL) subsidiary, Clarion Clinics Group, has begun accepting registrations of interest from potential patients for two new psychedelic-assisted therapy (PAT) treatments at its website clarionclinics.com. The PAT t...

Incannex Healthcare has completed a constructive pre-Investigational New Drug Application (pre-IND) meeting with the US Food and Drug Administration (FDA) for its proprietary drug product IHL-675A for treatment of rheumatoid arthritis (RA)....

Incannex Healthcare (IHL) completes a pre-IND application meeting with the US FDA for its drug product, IHL-675A IHL-675A is a unique combination of CBD and HCQ to treat rheumatoid arthritis and other inflammatory disorders The FDA’s...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug (pre-IND) application meeting with the US Food and Drug Administration (FDA) relating to it...

Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug (pre-IND) application meeting with the US Food and Drug Administration (FDA) relating to its proprietary drug product IHL-675A for the treatment of rheumatoid arthr...

Incannex Healthcare has successfully submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for IHL-42X for treatment of obstructive sleep apnoea.   Incannex Healthcare (ASX:IHL) said the IND do...

What a time to be alive. As the clock struck midnight to herald the start of the 23/24 financial year, Australia’s ability to legally prescribe through qualified medical practitioners MDMA (ecstasy) and psilocybin – the active ingredient in...

Incannex Healthcare (IHL) submits an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) The application is for IHL-42X, a novel medication for OSA treatment IHL-42X is a synergistic composition of...

This content is created by Smallcaps Authors. [Author : Colin Hay] Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has achieved another milestone with the development approval for new product targeting the $15 billion...

PYC Therapeutics to advance to Phase 2 clinical trial Osteopore announced new CEO and non-executive director Incannex has as engaged Fortrea to manage its Phase 2/3 clinical trial   PYC to advance to Phase 2 after toxicology tests RNA dru...

Incannex has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation (CRO) for management of the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of obstructive sleep apnoea (OSA). Incannex Healthcare (...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Incannex Healthcare (ASX: IHL) has engaged global company Fortrea as the contract research organisation for management of its investigational new drug opening Phase 2/...

Incannex has been given the green light to start its Phase 2 clinical trial to assess the safety and efficacy of IHL-675A, a combination drug that combines a specific proprietary formulation of CBD and another long standing prescription dru...

Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia   With regulations on cannabis use moving fast...

Incannex Healthcare (IHL) receives approval from the Belberry Human Research Ethics Committee (HREC) for its phase two clinical trial of IHL-675A The company will commence the trial at its lead site, Emeritus Research in Camberwell, Vict...

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move on Thursday. In morning trade, the cannabis-focused pharmaceutical company’s shares are up 4.5% to 12 cents. Why is the Incannex share price rising? Investors have been bu...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Medicinal cannabinoid and psychedelic therapies development company Incannex Healthcare (ASX: IHL) has received approval from Bellberry Human Research Ethics Committee...

Incannex Healthcare (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee for the lead site, Emeritus Research in Victoria, for its Phase 2 clinical trial.

The ASX will rise once again after softer than expected CPI in the US Elon Musk announces new AI company Cathie Wood’s ARK sold US$12 million worth of Coinbase shares   The ASX 200 index is set open higher once again on Thursday, trackin...

Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson   Amidst gro...

The S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. In afternoon trade, the benchmark index is down 0.4% to 7,011.8 points. Four ASX shares that are falling more than most today are listed below. Here’s why...

This content is created by Smallcaps Authors. [Author : Colin Hay] Australian pharmaceutical cannabinoid product developer Incannex Healthcare (ASX: IHL) (NASDAQ: IXHL) has unveiled its intentions to relocate to the United States, with pl...

Bod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech received an ethics approval to begin Phase I/II clinical trial Incannex intends to list all its shares on the Nasdaq   Bod Science provides ‘landm...

The days of Incannex Healthcare Ltd (ASX: IHL) shares trading on the ASX boards are now numbered. That’s because this morning, the cannabis focused clinical stage pharmaceutical development company has announced plans to redomicile from...

Incannex Healthcare (IHL) receives ethics approval to commence a bioavailability/bioequivalence trial to assess the pharmacokinetics and tolerability of its obstructive sleep apnoea treatment Bellberry Human Research Ethics Committee app...

Imricor jumps 13pc after securing $30m in funding Singular Health signs a master distribution agreement in the US Louie the Beagle has passed the 1-year mark taking PharmAust’s Monepantel Imricor jumps 13pc on funding deal Imricor Medica...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage pharmaceutical company Incannex Healthcare (ASX: IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability...

Incannex is looking to replicate results from last year’s Phase-II proof of concept clinical trial of IHL-42X for treatment of obstructive sleep apnoea (OSA) in its upcoming long term multi-site pivotal study. Incannex Healthcare (ASX:IHL)...

ASX cannabis shares have had a tough year. That’s despite the fact that the cannabis stocks operate in a country where medicinal marijuana is technically legal. That’s enabled them to provide valuable health services to many thousands...

It was only last month that we were discussing Incannex Healthcare Ltd (ASX: IHL) shares and the epic run they had been on over the previous five years. Yes, back in May, investors who had held onto Incannex shares were up a lucrative 425%...

Zelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica Diabetes is a huge market, estimated at a massive US$62 billion in 2022 Stockhead reached out to Zelira’s CEO, Dr. Oludare Odumosu   Diabetes is one of the lea...

Highlights Incannex Healthcare Limited (ASX: IHL) is a clinical-stage pharmaceutical development company This stock has corrected 61% in the last one year through 19 June 2023 On Friday (16 June 2023), the company announced it recruit...

The ASX is tracking higher in midday trade, up six per cent. AGL Energy (AGL) is top of the pack on the ASX 200 today after announcing a massive profit upgrade. Energy and utilities have been the biggest gainers so far. In ASX news, Nex...

Incannex Healthcare has recruited two highly experienced lead principal investigators (PIs) for the IND opening Phase-2/3 clinical trial investigating IHL-42X cannabinoid treatment of obstructive sleep apnoea (OSA). The company has appointe...

Incannex Healthcare (IHL) recruits two principal investigators to lead a phase 2/3 clinical trial for its cannabinoid drug, IHL-42X, to treat obstructive sleep apnoea Doctor John D Hudson of FutureSearch Trials of Neurology and Doctor R...

This content is created by Smallcaps Authors. [Author : Colin Hay] Incannex Healthcare (ASX: IHL) has taken another key step in its studies to help improve the comfort of millions of sleep apnoea sufferers and destruct a multi-billion dol...

The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week   For years, people have frowned upon ps...

Incannex Healthcare has announced that three of the world’s top psychedelic therapy and science experts with significant media profiles have joined the advisory board of its subsidiary Clarion Clinics Group. Medicinal cannabis and psychedel...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has announced that global psychedelic therapy and science experts Doctor Bill Richards...

Got 90 seconds? Then listen to Director, Peter Widdows tell us about their company news. Medicinal cannabis and psychedelic therapies company, Incannex Healthcare (ASX:IHL), subsidiary Psychennex, is a psychedelic-assisted psychotherapy com...

Incannex’s psychedelics focused subsidiary, Psychennex, believes that it has the best team of experts to capture the emerging opportunities in psychedelic-assisted psychotherapy. Medicinal cannabis and psychedelic therapies company, Incanne...

It’s been a while since ASX cannabis stocks have been popular with ASX investors. They were all the rage a few years ago with many cannabis shares recording triple-digit gains over 2020 and 2021. But the hype has decidedly died down over 2...